According to ASCO/CAP guidelines, ERBB2 amplification in just 20 adjacent BC cells suffices to establish a HER2-positive status, even if all other parts of the tumor are negative for HER2 protein expression and ERBB2 amplification [4]. This evidence concerns the gene ERBB2 and neoplasm.